Patients with hematologic malignancies who relapse after their first hematopoietic stem cell transplantation tend to have poor prognoses. One option for these patients is a second allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there are few reports of second allo-HSCT therapy in children with relapsed hematologic malignancies. Patient outcomes in 27 individuals with ac...

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of continuing chemotherapy or transplantation using either autologous or allogeneic stem cells. Patients with favorable subtypes of AML generally receive chemotherapeutic consolidation, although recent studies have also suggested favorable outcome after hematopoietic stem cell transplantation (HSCT). Although alloge...

[email protected] Abbreviations ABMR: Antibody Mediated Rejections; ADMSC: Adipose Tissue Derived Mesenchymal Stem Cells; AHG: Anti-Human Globulin; ASHI: American Society of Histocompatibility and Immunogenetics; CGN: Chronic Glomerulonephritis; CNI: Calcineurin Inhibitor; CRF: Chronic Renal Failure; DMEM: Dulbecco’s Modified Eagle’s Medium; DSA: Donor Specific Antibody; DST: Donor Specifi...

Acute myeloid leukemia (AML) (also called acute nonlymphocytic leukemia) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into a variety of post-remission strategies using either allogeneic or autologous hematopoietic stem-cell transplantation (HSCT). HSCT refers to a procedure in which hematop...

Acute myeloid leukemia (AML) (also called acute nonlymphocytic leukemia) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into a variety of post-remission strategies using either allogeneic or autologous hematopoietic stem-cell transplantation (HSCT). HSCT refers to a procedure in which hematop...

Specific protocols define eligibility, conditioning, donor selection, graft composition and prophylaxis of vs. host disease for children young adults undergoing hematopoietic stem cell transplant (HSCT). However, international rarely, if ever, detail supportive care, including pharmaceutical infection prophylaxis, physical protection with face masks cohort isolation or food restrictions. Suppor...

Specific protocols define eligibility, conditioning, donor selection, graft composition and prophylaxis of vs. host disease for children young adults undergoing hematopoietic stem cell transplant (HSCT). However, international rarely, if ever, detail supportive care, including pharmaceutical infection prophylaxis, physical protection with face masks cohort isolation or food restrictions. Suppor...

BACKGROUND Long-term outcome after hematopoietic stem cell transplantation including late transplant-related events is of increasing interest. The aim of this study was to evaluate the incidence of cardiovascular events after allogeneic HSCT and to search for their risk factors. DESIGN AND METHODS This is a retrospective multicenter European Group of Blood and Marrow Transplantation (EBMT) an...

The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosuppressive drugs after HSCT is crucial. This case report demonstrates that rapamycin and GVL repre...

Introduction: To assess the use of nutritional support in children and adolescents submitted to autologous hematopoietic stem cell transplantation (HSCT), analyze changes status at hospital discharge after HSCT. Methods: A retrospective observational study was conducted on pediatric oncology patients hospitalized for HSCT between 2010 2017. Nutritional therapy evaluated based duration enteral t...